Figure 3
Anti-HSV-1 activity of c-exNDI. (a) Plaque assay: Vero cells were infected with HSV-1 strain F (MOI 1, as previously reported27) and treated with increasing concentrations of c-exNDI (0.7 nM–100 nM). Supernatants were collected 24 h.p.i. and the number of plaque forming units was determined. (b) Vero cells were treated at the same concentrations of c-exNDI (0.7 nM–100 nM) used in the antiviral assay and cytotoxicity was evaluated by MTT assay. (c) Flow cytometry of HSV-1 [V41]-infected cells treated with c-exNDI and ACV. HSV-1 [V41]-infected cells were used as positive control and their GFP fluorescence set to 100%. C-exNDI (red curve) and ACV (orange curve)-treated infected cells were compared to HSV-1 [V41]-infected cells (green curve) to monitor compound inhibition of GFP fluorescence. (d) Quantification of the mean of GFP fluorescence upon treatment of HSV-1 [V41]-infected cells with c-exNDI and ACV, observed in (b).
